Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SAR 439459

Next Previous
Drug Profile

SAR 439459

Alternative Names: Anti-TGFb SAR-439459; Anti-transforming Growth Factor-beta mAb SAR439459; SAR-439459

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sanofi
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Transforming growth factor beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Osteogenesis imperfecta
  • Discontinued Solid tumours

Most Recent Events

  • 10 Aug 2023 SAR 439459 is still in phase I clinical trials for Osteogenesis imperfecta in USA (IV) (Sanofi pipeline, June 2023)
  • 10 Feb 2023 Discontinued - Phase-I for Osteogenesis imperfecta in USA (IV) (Sanofi pipeline; February 2023 )
  • 03 Jun 2022 Efficacy and adverse events data from a phase I/Ib trial in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top